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Abstract
Senescent and suppressor T cells are reported to be increased
in select patients with cancer and are poor prognostic
indicators. Based on the association of these T cells and poor
outcomes, we hypothesized that tumors induce senescence in
T cells, which negatively effects antitumor immunity. In this
report, we show that human T cells from healthy donors
incubated with tumor for only 6 h at a low tumor to T-cell
ratio undergo a senescence-like phenotype, characterized by
the loss of CD27 and CD28 expression and telomere
shortening. Tumor-induced senescence of T cells is induced
by soluble factors and triggers increases in expression of
senescence-associated molecules such as p53, p21, and p16.
Importantly, these T cells are not only phenotypically altered,
but also functionally altered as they can suppress the
proliferation of responder T cells. This suppression requires
cell-to-cell contact and is mediated by senescent CD4+ and
CD8+ subpopulations, which are distinct from classically
described natural T regulatory cells. Our observations support
the novel concept that tumor can induce senescent T cells with
suppressor function and may effect both the diagnosis and
treatment of cancer. [Cancer Res 2008;68(3):870–9]
Introduction
Tumor immune evasion is now increasingly understood to be an
important process in carcinogenesis. One of the best-characterized
forms of immune evasion is tumor-induced apoptosis (TIA) of
immune effector cells, resulting in an inadequate immune response
(1, 2). Similar to apoptosis, other forms of cell death, such as
senescence, are recognized as important in limiting immune cell
survival (3, 4). T-cell senescence was originally a concept of aging.
However, others have observed senescence in T lymphocytes
during chronic infections and some tumor processes (5–7). Vallejo
(8) recently proposed that during aging, immune remodeling
occurs, leading to T-cell senescence. Similarly, this remodeling
leads to premature T-cell senescence in younger patients with
chronic diseases and cancer. Premature senescence is a type of
cellular dysfunction that can be triggered by multiple signals such
as oxidative stress, DNA damage, oncogene activity, and telomere
uncapping (9). Despite the recognition of senescent T cells in
cancer patients, the cause and ramifications remains poorly
understood.
Tumor-infiltrating lymphocytes (TILs), upon entering the tumor
microenvironment, encounter very high tumor to T-cell ratios and
result in TILs undergoing TIA (1, 10). Models have been created to
reproduce this process in vitro by coincubating tumor with T cells
at relatively high tumor to T-cell ratios and for prolonged time
intervals (1). Similarly, chemotherapies induce apoptosis at
relatively high concentrations of drug. In the field of chemotherapy,
lower concentrations of these chemicals induce a senescence-like
phenotype in which the cells continue to be metabolically active
but do not proliferate (11). We hypothesized that tumor coin-
cubated with T cells at a low tumor to T-cell ratio can induce a
state of T-lymphocyte senescence similar to that seen in the low-
dose chemotherapy model.
Senescent T cells are usually characterized by loss of costimu-
latory molecules such as CD27 and CD28 (12). Another mechanism
considered an important marker of senescence is telomere
shortening (13). Moreover, there are many proteins implicated in
cellular senescence including the cell cycle regulation molecules
p53, p21, and p16 (9). In addition, activation of ATM DNA damage
response and heterochromatinization of the nuclear genome are
found in senescent cells (14). Despite numerous known molecular
markers of senescence, the signal that triggers senescence in
T lymphocytes is not well-understood.
Interestingly, CD8+ T cells with senescent phenotypes have
significant suppressor function (5, 15). These CD8+ suppressor cells
are up-regulated in various cancers studies, but no direct connection
to cellular senescence has been made (6). Unlike CD8+ T cells, little is
known about the suppressor function of CD4+ T cells with senescent
features. Finally, it is not clear whether CD4+ or CD8+, CD28
senescent T lymphocytes shown to be increased in cancer patients
have suppressor function (4).
In this study, we sought to understand the mechanisms by which
tumors induce senescent T cells and the downstream effects of this
form of immunosuppression on the tumor host interaction. We
show a tumor-induced senescence (TIS) process of T cells after a
single brief coincubation in conditions of a low tumor to T-cell
ratio. Furthermore, we show that both CD8+ and CD4+ senescent
T lymphocytes suppress proliferation of normal T cells. We propose
that tumors directly induce senescent features in T cells, changing
them functionally into suppressor cells, and that this process is a
novel mechanism of tumor immune evasion.
Materials and Methods
Purification of T Cells
Human peripheral blood mononuclear cells (PBMC) from healthy donors
(ages 25– 40 years) were isolated by centrifugation over Ficoll-Hypaque
gradients (GE Healthcare Bio-Science AB). T cells were purified from PBMCs
by negative selection using the Pan T-Cell Isolation kit II (Miltenyi Biotech),
according to the manufacture’s instructions. For some experiments, CD4+
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and CD8+ were purified by positive selection from total T cells using CD4 or
CD8 Microbeads (Miltenyi Biotech). The purity of each population was
routinely checked and was >95% pure as determined by fluorescence-
activated cell sorting (FACS) staining.
Cell Lines
Squamous cell carcinoma of the head and neck 012SCC, breast
carcinoma cell line MCF-7, human colon carcinoma cell line HCT-116,
and melanoma cell line MEL-624 were cultured in DMEM (Cellgro). Jurkat
T leukemic cell line and T cells derived from healthy donors were cultured
in RPMI 1640 (Cellgro). All medium was supplemented with 10% fetal
bovine serum (FBS; Atlanta biologicals), 1% glutaMax (Life Technologies),
25 mmol/L Hepes (Life Technologies), and 1% penicillin/streptomycin (Life
Technologies). Human dermal fibroblasts (HDF; ScienCell Research
Laboratories) from healthy donors were cultured in fibroblast medium
containing 10% FBS and Fibroblast Growth supplement.
Induction of Senescence by Tumor Cell Lines
To induce senescent T cells, tumor cell lines (012SCC, MCF-7, HCT-116,
and MEL-624) or HDF were cultured for 24 h, then CD3+, CD4+, or CD8+
T lymphocytes, or Jurkat T cells were added to the wells containing complete
culture medium (referred as control T cells) or tumor cells at a tumor:T-cell
ratio of 1:1 (TIS-T group) and incubated for 6 h. As apoptotic controls, the
same conditions were repeated except with a tumor:T-cell ratio of 40:1, or
T cells were cultured with the apoptotic-inducing chemotherapy, Etoposide
(Vp16; 30 Amol/L) for 12 h. Then, the T cells were collected, washed, and
cultured for 7 days in complete medium; no additional cytokines were added.
Routinely on day 7, cell viability of control T cells (89 F 7.5) or TIS-T
(62 F 3.2) was checked by Trypan Blue. T cells collected after coincubation
with tumor cell lines were analyzed by FACS and found to be 99% CD3+.
Flow Cytometry
Apoptosis in T cells or Jurkat cells was assessed by staining cells with
FITC-labeled Annexin V and propidium iodide (BD PharMingen) according
to the manufacture’s instructions.
TIS-T or control T cells were incubated with allophycocyanin-labeled
anti-human CD28, phycoerythrin-labeled anti-human CD27, or isotype
control (BD PharMingen) for 30 min at 4jC in the dark.
TIS-T and control T cells were fixed with ethanol and incubated at 20jC
for 2 h. The cells were incubated with FITC-labeled anti-human p16
monoclonal antibodies (mAb) or isotype control (BD PharMingen) for
30 min at room temperature in the dark.
The length of telomere repeats at chromosome ends in TIS-T and control
T cells were measured using Telomere PNA kit/FITC for Flow Cytometry
(DakoCytomation) following the manufacture’s instructions. FITC-labeled
fluorescent calibration beads (Quantum TM-24 Premixed; Bangs Laborato-
ries) were used to convert telomere fluorescence data to molecules of
equivalent soluble fluorescence (MESF) units. The following equation was
performed to estimate the telomere length in bp from telomere
fluorescence in MESF units (bp = MESF  0.495; ref. 16).
All samples were analyzed on a BD LRSII with FACSDiva Software
(BD Bioscience).
Western Blot Analysis
Proteins were separated by SDS-PAGE and transferred to polyvinylidene
difluoride membranes, as described previously (17). The membranes were
incubated with antibodies against either p53 (Santa Cruz), p21 (Abcamb),
p16 (Santa Cruz), or h-actin (Cell Signaling) and then with horseradish
peroxidase–conjugated secondary antibody. The protein bands were
detected by enhanced chemiluminescence (Pierce).
Evaluation of DNA Damage
To analyze DNA damage foci, the expression of known senescence-
associated markers, ataxia telangiectasia–mutated (ATM) kinase ATM
(Ser1981), phosphorylated histone H2AX (g-H2AX), and a marker for
histones, heterochromatin protein 1 (HP1)-h, were assessed. TIS-T or
control T cells were fixed for 20 min in 4% paraformaldehyde. After
permeabilization, the cells were blocked with 3% bovine serum albumin.
The samples were first incubated with anti-ATM (Ser1981; Abcam) or anti–
HP1-h (Abcam) overnight. After a fixation with 4% paraformaldehyde and
inactivation with 25 mmol/L glycine PBS, the samples were incubated with
anti–g-H2AX (S139; Upstate) for 1 h. Samples were incubated with Alexa 488
Fluor goat anti-mouse and Alexa 647 Fluor goat anti-rabbit secondary
antibodies. The cells were centrifuged onto microscopic glass slides and
examined using fluorescent microscopy.
In vitro Proliferation, Immunosuppression Assay, and Mixed
Lymphocyte Reaction
Proliferation analysis. To analyze the proliferative capacity of TIS-T
cells in response to polyclonal activation, plates were coated overnight at
4jC with 1 Ag/mL of anti-CD3 mAb (BD PharMingen). Then, TIS-T or
control T cells (2  105 cell/well) were cultured for 3 days. The cells were
then pulsed for 18 h with 1 ACi (0.037 MBq)/well [3H]-thymidine, and [3H]-
thymidine uptake was evaluated.
Immunosuppression assay. Plates were coated overnight at 4jC with
1 Ag/mL of anti-CD3 mAb. Then, fresh autologous T cells (referred to as
responders) were plated with TIS-CD3+, CD4+, or CD8+ cells or control
T cells at various ratios for 3 days. Then, wells were either pulsed for 18 h
with 1 ACi/well, and the proliferative response was evaluated as describe
above, or the supernatants were collected for cytokine analysis. The levels of
INF-g (Diaclone), interleukin (IL)-6 (Diaclone), IL-10 (Diaclone), and trans-
forming growth factor (TGF)-h (R&D system) were measured by ELISA
following the manufacturer’s instruction.
To assess whether TIS-T cells exert their regulatory function through
direct cell contact or through release of soluble factors, we used Transwell
inserts. TIS-Tor control T cells were added in the upper chamber at a ratio of
1:3 to autologous anti-CD3–stimulated responder cells seeded in the lower
chamber. After 3 days, the proliferative response was evaluated as described.
Mix lymphocyte reaction. Autologous T cells (1.5  105/well) were
seeded with irradiated (3,000 rad) allogeneic PBMC (1.5  105/well) and
irradiated TIS or control T cells (0.5  105/well) for 4 days. Then, the
proliferative response was evaluated as described.
Statistical Analysis
The statistical significance was analyzed using unpaired Student’s t test.
Values were considered statistically significant when P value is <0.05. All
experiments were repeated at least four times and error bars represent
the SD.
Results
Tumor-induced senescence — a distinct phenomenon from
TIA. To test our hypothesis that a low tumor to T-cell ratio could
induce senescence, we coincubated the 012SCC cell line with a
T-cell line Jurkat at both low and high tumor to T-cell ratios. We
observed that Jurkat cells pretreated at a tumor:T-cell ratio of 40:1
for 6 h were apoptotic after 2 days of culture as indicated by
increased staining with Annexin V and propidum iodide (Fig. 1A).
However, Jurkat cells pretreated at tumor:T-cell ratios of 5:1 to 0.5:1
also for 6 h did not show the augmentation of Annexin V/
propidum iodide staining after 2 days of culture, indicating the
absence of apoptosis (Fig. 1A). To evaluate the senescence
phenotype, we used loss of CD28 as an indicator of senescence
(18). On day 2, the loss of expression of CD28 was similar in Jurkat
cells preexposed to high and low tumor to T-cell ratios (Fig. 1B).
As expected, Jurkat cells pretreated with a high number of 012SCC
did not survive beyond 2 days of culture. However, Jurkat cells
pretreated at a low tumor to T-cell ratio survived and showed a
significant loss of CD28 expression by day 7, suggesting that these
cells became senescent (Fig. 1D). Consistent with models of low
dose chemotherapy inducing a senescent-like process, these TIS-T
cells showed increased staining with Annexin V (Fig. 1C ; ref. 19). In
addition, this is in line with studies showing normally associated
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apoptotic molecules functioning in nonapoptotic processes (20).
Taken together these results show that short term exposure of
Jurkat cells to lower tumor to T-cell ratios induce a senescence-like
phenotype.
TIS is induced in T cells from healthy donors. To evaluate if
the TIS process could occur in normal T cells, we purified CD3+
cells from healthy donors and placed them with complete medium
alone, O12SCC tumor cell line at a low tumor to T-cell ratio (1:1), or
a high ratio (40:1) for 6 h. Parallel studies were performed with
VP16, an apoptotic inducing reagent. After 2 days, only 10% of
T lymphocytes cultured with medium alone were Annexin
V+/propidum iodide+. As expected, we observed increased per-
centage of Annexin V+/propidum iodide+ T cells preincubated with
a high tumor to T-cell ratio or with etoposide (46% and 43%,
respectively). In contrast, only 15% of T cells preincubated with
O12SCC tumors at a low tumor:T-cell ratio (1:1) were Annexin
V+/propidum iodide+ (Fig. 2A).
Because normal T cells express CD27 and CD28, we used the loss
of both of these cell surface markers as an indicator of senescence.
After 2 days of culture, no group of T cells exhibited a senescent
phenotype (Fig. 2A). After 7 days, T cells that had been exposed to
apoptotic conditions were no longer in culture. However, as shown
in Fig. 2B , T lymphocytes preincubated at a low tumor to T-cell
ratio exhibited a significant decrease (55% F 7%) of CD27/CD28
expression compared with control T cells (10% F 4%). In addition,
by day 7, T lymphocytes preincubated with a low tumor to T cell
low ratio exhibited an increment in the expression of Annexin V
compared with control T cells.
Interestingly, we observed that anti-CD3–stimulated T cells were
able to undergo TIS at a higher extent than unstimulated T cells
(data not shown).
We have observed that TIS-T cells on day 7 exhibit not only an
increment in Annexin V but also the activation of caspase 3 and 7.
The addition of a pan-caspase inhibitor (QVD-OPH) did reduce the
expression of these caspases in TIS-T cells but did not block the
senescence induced by tumor cells, but amplified it instead (data
not shown).
One of the major indicators of senescence is telomere shorten-
ing. Using a flow-fluorescence in situ hybridization (FISH) cyto-
metric assay, we determined telomere length in T lymphocytes
incubated with medium alone (control T cells) or pretreated for
6 h with either VP16 or O12SCC tumor cells at a 1:1 tumor:T cell
ratio. As shown in Fig. 2C , after 2 days of culture, all groups
exhibited similar telomere lengths. Importantly, at day 7, control
T cells grown in medium alone had no significant change in
telomere length; however, T cells pretreated at a low tumor to T-cell
ratio had a statistically significant decrease in telomere length
compared with the control group (P < 0.03).
Lack of proliferative capacity is another hallmark of senescence.
Freshly isolated T cells, control T cells (cultured with medium), or
Tcells pretreated with a low ratio of O12SCC tumor were stimulated
by immobilized anti-CD3 antibody, and proliferation was measured
by 3H-thymidine uptake. TIS-T cells showed a significant reduction
in proliferation compared with fresh or control T cells (Fig. 2D).
Taken together, these results indicate that pretreatment of
T lymphocytes with a low tumor to T-cell ratio for 6 h induces a
senescence-like phenotype.
T-cells senescence is induced by tumor cells but not by
normal cells and requires soluble factor(s). To assess whether
the TIS process was isolated to the 012SCC cell line or a more
generalized phenomenon, we examined other tumor cell lines.
T lymphocytes were pretreated with the following tumor cell lines:
MEL-624, MCF-7, and HCT-116, as described. T lymphocytes
pretreated with these tumor cell lines exhibited similar or even
greater losses of CD27/CD28 (50% F 4% for Mel-624, 60% F 3% for
MCF-7, and 61% F 3% for HCT-116). In contrast, HDF, under the
Figure 1. 012SCC can induce apoptosis or
senescence depending on the tumor to
T-cell ratio of coincubation. The T-cell line
Jurkat was coincubated with 012SCC cell
line in tumor:T-cell ratios of 40:1, 5:1, 1:1,
or 0.5:1 for 6 h. Jurkat T cells were washed
and cultured in complete medium for 7 d.
A to B, after 2 d, using flow cytometry,
we studied the apoptotic markers Annexin V
and propidum iodide (PI ), as well a
senescent marker (% CD28 loss ) in each
group of T cells. C to D, on day 7,
Annexin V and CD28 loss were evaluated.
Columns, mean; bars, SE.
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same conditions, did not induce down-regulation of CD27/CD28
expression (12% F 3%; Fig. 3A), indicating that senescence is
induced only by tumor cells.
To evaluate whether the induction of a senescence-like phenotype
requires cell-to-cell interaction, we repeated our TIS model but
separated the tumor cells from T lymphocytes with a Transwell
insert. We observed no change in the level of the down-regulation of
CD27/CD28 expression, indicating that TIS of T cells is mediated by
soluble factors (Fig. 3B).
Cell cycle–regulating and DNA damage–responding mole-
cules are involved in TIS-T cells. Various pathways leading to
senescence have been described, suggesting a direct connection to
cell cycle machinery. For this reason, we analyzed the expression of
the cell cycle–controlling molecules, p53, p21, and p16, in TIS-T
cells. Using Western blot analysis, we detected distinct increases in
p53, p21, and p16 on day 7 in T cells pretreated with a 1:1 tumor:T-
cell ratio versus control or fresh T cells. Although p53 was most
strikingly increased, there were clearly differences in the expression
of p21 in the TIS group (Fig. 4A). Because others have shown p16
changes are best seen by flow cytometry, and our results by
Western blot were modest, we next studied the expression of p16
by FACS on TIS-T cells and control T cells and found that the
former group had a significant increase in the expression of this
molecule (Fig. 4B ; ref. 21).
There have been a number of recently discovered DNA damage
changes that cause heterochromatinization that are indicative of
senescence (14). Figure 4C shows that TIS-T cells consistent with
reported senescence DNA damage changes displayed activated
ATM (Ser1981) and higher expression of g-H2AX with colocalization
compared with control T cells. In models of DNA damage in
Figure 2. Induction of TIS-T cells. Peripheral Tcells from healthy donors were coincubated with the tumor cell line 012SCC in tumor:T-cell ratios of 1:1 or 40:1 for 6 h, or
with VP16 for 12 h. T cells were washed and cultured in complete medium for 2 or 7 d. A, after 2 d, by flow cytometry, we studied the apoptotic markers Annexin V
and propidum iodide, as well as senescent markers (loss of CD28 and CD27 represented as % CD28 CD27 T cells in CD3+-gated cells) in each group and in
T cells cultured with medium alone (control T). B, on day 7, we evaluated loss of CD28 and CD27 and the expression of Annexin V in TIS-T cells incubated with tumor
in a 1:1 ratio and in T cells cultured with medium alone (control T). Inserts, percentage of cells within respective quadrants. C, telomere length of freshly isolated
T cells or T cells cultured in medium (control T) or T cells previously incubated with tumor at a 1:1 ratio (TIS-T) or with VP16. Telomere length is represented as mean of
telomere length + SD. D, after 7 d, T cells cultured in medium (control T) or previously incubated with tumor at a 1:1 ratio (TIS-T) were stimulated with immobilized
anti-CD3 antibody (1 Ag/mL) for 3 d and pulsed with 3[H] dTh. Fresh T cells were processed in parallel as control. T-cell proliferation was evaluated by 3H Thymidine
incorporation and represented as mean counts per minute (cpm) + SD. *, P = 0.027 versus control T cells (C ); *, P < 0.0002 versus control T cells (D ). Results
are representative of four independent experiments from different donors.
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stimulated lymphocytes, phosphorylated histones have been shown
to be diffusely expressed as opposed to controls that are usually
seen in focal distribution (14, 22). The expression of phosphory-
lated histones in TIS-T cells, similarly, were seen diffusely as
opposed to the punctate expression in the control T cells.
Consistently, we observed that only TIS-T cells display diffuse
staining for another distinct marker of heterochromatin, HP1h,
another DNA damage indicator (Fig. 4D). These results indicate
that TIS induces DNA damage that may activate heterochroma-
tization, a hallmark of cellular senescence.
TIS-T cells are able to suppress antigen nonspecific and
allogeneic-induced proliferation of T cells. Both senescent and
some suppressor T cells have similar phenotypes, suggesting that
they may be the same population. We thus evaluated the ability of
TIS-T to suppress T-cell proliferation. Figure 5A depicts that
control T cells did not significantly alter the anti-CD3–induced
proliferation of responder T cells ( freshly purified autologous CD3+
cells) at any control T cell to responder ratio tested. In contrast,
TIS-T cells even at a 1:30 TIS-T cell:responder ratio were able to
induce a profound reduction of anti-CD3–induced proliferation of
responder cells. We further confirmed this phenomenon by a mixed
lymphocyte reaction (MLR). Freshly isolated responder T cells were
incubated with irradiated allogeneic PBMCs in the presence of
irradiated TIS-T or control T cells, and proliferation was measured
by 3H-Thymydine uptake. As shown in Fig. 5B , contrary to control
cells, TIS-T cells strongly suppressed the proliferation of responder
cells induced by MLR.
The expression of particular cytokines has been associated
with specific T suppressor cells (23). For instance, although
CD4+CD25highFoxp3+ T regulatory cells (T-regs) secrete IL-10 and
TGF-h, CD8+CD28 suppressor cells secrete INF-g and IL-6 (24, 25).
Our data (Fig. 5C) indicate that the levels of INF-g and IL-6
production was significantly increased only in the supernatant of
TIS-T cells in coculture with anti-CD3–stimulated responder cells.
In contrast, IL-10 and TGF-h production was similar in all groups.
TIS occurs comparably in CD4+ and CD8+ T cells and causes
the loss of natural T-regs. Because senescence changes have been
shown to preferentially occur in CD8+ versus CD4+ T lymphocytes
(4), we analyzed TIS susceptibility in these subpopulations. CD4+
or CD8+ T lymphocytes isolated from PBMC of healthy donors
were preincubated with O12SCC at a low tumor to T-cell ratio
and expression of senescence markers was analyzed by FACS.
Figure 6A shows that under this condition, both CD4+ and CD8+
T cells lost CD27 and CD28 expression, indicating that both
populations were susceptible to TIS. We also showed (Fig. 6B)
that telomere shortening occurred similarly between the CD4+
and CD8+ groups, confirming their senescence status. In addition,
we observed no significant changes in the CD4:CD8 ratio in TIS-T
cells compared with control T cells after 7 days of culture (data
not shown).
Figure 3. TIS of T cells is induced by several tumor cell lines and does not require cell-to-cell contact. A, peripheral T cells from healthy donors were coincubated
with the tumor cell lines MEL-624, MCF-7, and HCT-116 or HDF from healthy donor in a 1:1 tumor:T-cell ratio for 6 h. T cells were washed and cultured in complete
medium for 7 d. After 7 d, using flow cytometry, we evaluated loss of CD28 and CD27 in each group of T cells. B, T cells were coincubated in direct contact with
012SCC tumor cell line (TIS-T) or separated by a Transwell semipermeable membrane (TIS-T-TW ) in a 1:1 tumor:T-cell ratio for 6 h. The cells were washed
and cultured in complete medium. After 7 d, loss of CD28 and CD27 was evaluated by flow cytometry in these two groups and in T cells cultured with medium
(control T). Inserts, percentage of cells within respective quadrants. Results are representative of four independent experiments from different donors. APC-A,
allophycocyanin-area.
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We next tested whether immunosuppression by TIS-T lympho-
cytes is mediated by CD4+ or CD8+ cells. Figure 6C shows that both
TIS-CD4+ and -CD8+ cells produced an equal and significant
abrogation of proliferation of responder T cells. Taken together, our
data indicate that in TIS of T cells, there is a parity of changes
within both CD4+ and CD8+ populations.
We next decided to assess whether TIS-CD8+ and -CD4+
T suppressor cells exert their regulatory function through direct
contact or release of soluble factors. For that, we separated the TIS-
T cells and responder T cells with Transwell insert. We observed
(Fig. 6C) that the suppression induced by TIS-T cells, TIS-CD4, or
TIS-CD8 cells was abrogated when they were separated by a
semipermeable membrane from the anti-CD3–stimulated T res-
ponders. Consistently neutralizing anti–IL-6 or anti–INF-g mAbs
had little effect on the suppression of T cells cultured in direct
contact with TIS-T cells (data not shown). These results indicate
that both TIS-CD4 and TIS-CD8 T cells inhibit the proliferation of
responder cells through direct cell-to-cell contact. Although TIS-T
cell suppressor function was associated with expression of specific
cytokines (Fig. 5C), they were not necessary.
To exclude the possibility that the suppression observed was
mediated by natural T-regs, we studied FACS phenotypic markers
expressed by T-regs (CD4+CD25highFoxp3+) in TIS-T cells. We found
that 2.8% of T lymphocytes in control T cells were CD4+CD25 high
and expressed Foxp3. In contrast, TIS-T cells lost all CD4+CD25high
cells (Fig. 6D). Although our data provide direct evidence that TIS-
T cells can suppress proliferation of responder T cells, this process
causes the loss of natural T-regs.
Discussion
Recent successes of immunotherapy has made the immune
system a realistic target for cancer treatment, but its limitations
has highlighted the dysfunction of immune effector cells in these
patients (26). Despite the potential significance of T-cell senes-
cence as a form of cancer-induced immunosuppression, its
pathophysiology is poorly understood (4). Based on models of
tumor immune evasion through apoptosis of T cells, we designed
an in vitro tumor microenvironment to test whether tumors could
directly induce senescence in T cells. We showed that lowering the
Figure 4. Cell cycle–regulating and DNA damage–responding molecules are involved TIS of Tcells. A, Western analysis of TIS-Tcells. Tcells from healthy donors were
either used fresh (1), cultured in complete medium for 7 d (2), or cocultured with the O12SCC tumor line at a 1:1 ratio for 6 h and then cultured in complete medium for
7 d (3). T cells from each group were lysed, and proteins were separated by SDS-PAGE. Gels were blotted to nitrocellulose membranes and then first probed with
anti-p53 before stripping and reblotting the membrane three more times with antibodies specific for p21, p16, and h-actin (protein-loading control). B, FACS analysis of
intracellular expression of p16 in TIS-Tcells (solid black line ), in control Tcells (dash line ), or isotype control (dotted line ). C to D, expression of DNA damage–responding
molecules. T cells from healthy donors were cultured in complete medium for 7 d (control T) or cocultured with the O12SCC tumor line at a 1:1 ratio for 6 h and
then cultured in complete medium (TIS-T). On day 7, DNA damage–responding molecules were evaluated by immunofluorescence. C, staining with 4¶,6-diamidino-
2-phenylindole (DAPI) to label DNA (I ); II, expression of g H2AX; III, expression of ATM (S1981); IV, merging of g H2AX and ATM (S1981). D, cells stained with DAPI (I );
II, expression of HP1-h. Magnification, 40 (C ) and 60 (D). Results are representative of four independent experiments from different donors.
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tumor to T-cell ratio could switch the T-cell response from
apoptosis to senescence. We also showed that a variety of cancers,
but not fibroblasts, can induce these changes in T cells.
Furthermore, tumors can induce senescence in T cells without
cell-to-cell contact, implying that soluble factor(s) may be
responsible. We are currently investigating whether these soluble
factors may be the same that induce T-cell apoptosis including
both proteins, such as FasL and other molecules such as
Figure 5. TIS-T cells suppress T-cell
proliferation in vitro. A, T cells from healthy
donors were incubated with the tumor cell
line 012SCC in a 1:1 tumor:T-cell ratio for 6 h and
then washed and cultured in complete medium.
After 7 d, TIS-T cells or T cells cultured in
medium for 7 d were added to fresh T cells
(responders) stimulated with immobilized
anti-CD3 antibody (1 Ag/mL) at the ratios
indicated in the figure. Responders T cells
stimulated with immobilized anti-CD3 antibody
were also used alone as control. After 3 d of
culture, the cell proliferation was evaluated by
3H Thymidine incorporation and represented
as mean of cpm + SD, or the culture
supernatants were collected for cytokine
detection. B, TIS-T cells obtained as described
above or T cells cultured alone in medium for
7 d were irradiated and then incubated with
fresh responder T cells in the presence of
irradiated, allogenic peripheral mononuclear
cells (MLR ). Responder T cells were incubated
with irradiated allogenic T cells only as a control.
After 4 d, responder T-cell proliferation was
evaluated by 3H Thymidine incorporation and
represented as mean of cpm + SD. C, TIS-T
cells are associated with the induction of
cytokine production. After 3 d of culture in the
condition mentioned above, TGF-h, IL-10, IL-6,
and INF-g production was evaluated in the
culture supernatant by ELISA. *, P < 0.002
versus control T:responder (1:3; control T:R ; A );
*, P < 0.0001 versus MLR control T (B); *,
P < 0.016 versus control T cell:responder (C );
**, P < 0.034 versus control T cell:responder (C ).
Results are representative of four independent
experiments from different donors. R, responder.
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gangliosides (1, 27). Strikingly, tumors induce senescence in
T cells after a brief interaction, which is in contrast to other
models of T-cell senescence where multiple repetitive signals are
required (28).
One of the markers to characterize T-cell senescence is the loss
of the cell surface expression of CD27 and CD28. Many studies have
shown these T-cell senescent features in cancer patients both in
the tumor microenvironment and in the periphery (6, 29). The
number of CD28 T cells, at least in the periphery, is an important
negative prognostic indicator in many cancer types (7, 30).
Furthermore, the loss of CD28 expression is associated with
immune dysfunction observed in cancer patients (31).
The loss of CD27 and CD28 in T cells has also been correlated
with their function as cytotoxic immune effectors (32). Interest-
ingly, unlike in the peripheral blood where CD27 and CD28 loss is a
poor prognostic indicator in the tumor microenvironment, the
opposite has been shown (33, 34). A potential explanation is that
patients with a better prognosis have higher rates of TIL-TIS,
whereas those with a poorer prognosis have a more aggressive
cancer leading to TIA. In a corroborating paper, higher rates of TIL
apoptosis correlated with a poorer prognosis in patients with colon
cancer (35). Another group recently showed that CD28 T cells
with suppressor function can represent >50% of all of the TILs in
many different cancer types and correlate with a poorer prognosis
(36). The difference in these articles most likely represents
emphasis and the heterogeneity that can be found in TILs some
with more detrimental qualities and others with appropriate
antitumor capabilities.
Figure 6. Effects of the TIS process on CD4+ and CD8+ Tcells and T-regs. A to B, purified CD4+ or CD8+ Tcells from healthy donors were incubated with the tumor cell
line 012SCC in a 1:1 tumor:T-cell ratio for 6 h and then washed and cultured in complete medium. CD4+ or CD8+ T cells cultured in medium were used as control.
A, on day 7, loss of CD28 and CD27 expression was evaluated by flow cytometry in CD4+ or CD8+ T cells placed in medium or previously incubated with tumor
(TIS). Inserts, percentage of cells within respective quadrants. B, on day 7, telomere length of CD4+ or CD8+ T cells cultured in medium or previously incubated
with tumor was measured by flow-FISH assay and represented as mean of telomere length + SD. C, control T, CD4+ or CD8+ T cells, or TIS-T, TIS-CD4, and TIS-CD8
were cultured in direct contact with immobilized anti-CD3–stimulated T cells (responder; I ) or separated from responder T cells with a semipermeable membrane (II )
and as control responder T cells alone (III ). After 4 d, T-cell proliferation was evaluated by 3H Thymidine incorporation and represented as cpm + SD. D, TIS-T
cells (right ) or T cells cultured alone in medium for 7 d (left ) were evaluated by flow cytometry for the expression of Foxp3 in the CD4+CD25high and CD4+
CD25 subpopulations. *, P < 0.008 versus CD4 control (B ); **, P < 0.0036 versus CD8 control (B); *, P < 0.003 versus control CD4:responder (C ); **, P < 0.0012
versus control CD8:responder (C ). Results are representative of four independent experiments from different donors.
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Our data indicate a delayed gain of Annexin V staining in TIS
conditions. The timing of Annexin V positivity correlates with other
models of senescent-like phenotypes (19). Increases in Annexin V
have been documented in CD27 or CD28 peripheral blood T cells
in patients with cancer and in the aging population (37, 38). One
group found that after successful resection of head and neck
tumors, the number of CD3+CD28 cells decreased (7). Their
explanation was that extirpation of the tumor removed the TIA
process. Alternatively, removal of the tumor could have caused an
abrogation of the TIS process. Our current model of TIS-T cells may
explain how patients with cancer can have increases in both
apoptotic and senescent T-cell phenotypes in the same peripheral
blood lymphocytes (39).
We confirmed the TIS process through other assays, such as lack
of proliferation, expression of senescence-associated molecules,
and telomere shortening. Telomere shortening occurs in older
individuals and in diseases that cause cellular senescence, and is a
diagnostic measure for this process (40). A recent publication using
TILs from melanoma patients for adoptive T-cell therapy showed a
correlation between longer telomeres and response to therapy (41).
Interestingly, the same group showed that TILs with lower CD27
and CD28 levels were less efficacious when used for immuno-
therapy (42).
Like senescent T cell, T suppressor cells are increased in patients
with cancer and in aging populations (4, 43). It has been proposed
that senescent T cells may have suppressor activity (4). A subset of
T suppressor cells that are CD8+CD28 has been described in both
the transplant and cancer literature (6, 44). Our results show a
strong ability of TIS-T cells to suppress proliferation of normal
T cells stimulated through a variety of inducers. Thus, the
importance of tumors inducing senescent T cells after a single
brief interaction is amplified by their the ability to, in addition,
cause the generation of T suppressor cells (18).
To characterize these TIS-T suppressor cells, we evaluated
potential immunosuppressive cytokines secreted during immuno-
suppression of normal T cells. We observed increases in INF-g and
IL-6 but not other cytokines such as TGF-h or IL-10. These former
two cytokines have already been shown to be associated with
CD8+CD28 suppressor cells (25). Although we found an associ-
ation between the expression of these cytokines and TIS-T
suppressor cells, these cytokines were not necessary but do have
diagnostic potential.
The TIS process is generated similarly in both CD4+ and CD8+
T-cell populations. Interestingly, in our TIS model, there was an
almost complete loss of natural T-regs (CD4+CD25highFoxp3+). One
possibility is that although CD28 suppressor/senescent cells,
which are apoptosis resistant, are induced, other cell types such as
CD4+CD25highFoxp3+ T cells undergo cell death instead (45). Others
authors have shown expansion of T-regs by coculture T cells with
various tumors. However, most of those studies were in mouse
models, and the expansion of T-regs required the addition of local
immature myeloid dendritic cells (46, 47). Our results reflect a
single interaction between human cancer cells and T cells, and
highlight only one form of immune evasion.
No data on CD4+CD28 suppressor cells exist in the literature
to date (23). One possibility is although CD4+CD28 cells are
increased in some cancer patients, they were not recognized as
suppressor cells (48). For instance, in resected melanoma speci-
mens, both CD4+ and CD8+ cells were found to have reduced CD28
levels but only in less dense areas of tumor. The authors argued
that these CD28 CD4+ and CD8+ cells were effective cytotoxic
cells. However, this may also be as a result of TIS as these T cells
were further from the tumor and potentially became unrecognized
senescent/suppressor cells (49).
Another plausible explanation for the lack of CD4+ suppressor
T cells in vivo is that there is a differential susceptibility to
senescence (and, thus, to become suppressor T cells) of CD8+ versus
CD4+ cells (50). It has been shown that after a repetitive set of
stimuli, CD8+ T cells are induced preferentially to senesce versus
their CD4+ counterparts (4). Potentially, in vivo , unlike our model,
there would be opportunity for repetitive stimuli from the tumor,
and thus, CD8+ cells may be more likely to have senescent/
suppressor features. Considering the importance of T suppressor
cells, confirming the existence of these CD4+CD28 suppressor cells
has ramifications not just for cancer but many others pathologies.
In conclusion, senescent T cells with suppressor function
observed to be increased in cancer patients can be reproduced
in vitro. If senescence is one of the major mechanisms of T-cell
dysfunction, this model then offers an environment to study this
phenomenon to understand the major pathways and potential
points of intervention. By reversing processes such as tumor-
induced T-cell senescence, modern immunotherapeutic modalities
can become a realistic approach as an alternative to traditional
cancer treatments.
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